Roquefort Therapeutics (LON:ROQ) Stock Price Down 14.9% – Should You Sell?

Roquefort Therapeutics plc (LON:ROQGet Free Report)’s share price fell 14.9% during mid-day trading on Tuesday . The company traded as low as GBX 3.18 ($0.04) and last traded at GBX 3.32 ($0.04). 1,854,913 shares traded hands during trading, an increase of 41% from the average session volume of 1,314,913 shares. The stock had previously closed at GBX 3.90 ($0.05).

Roquefort Therapeutics Stock Up 19.1 %

The stock has a market capitalization of £3.54 million, a price-to-earnings ratio of -274.00 and a beta of 0.05. The company has a quick ratio of 3.07, a current ratio of 0.79 and a debt-to-equity ratio of 12.37. The firm has a 50-day moving average of GBX 4 and a two-hundred day moving average of GBX 3.99.

Insider Transactions at Roquefort Therapeutics

In related news, insider Stephen Paul West bought 400,000 shares of the company’s stock in a transaction dated Tuesday, February 4th. The stock was acquired at an average cost of GBX 3 ($0.04) per share, with a total value of £12,000 ($15,001.88). 60.40% of the stock is currently owned by corporate insiders.

About Roquefort Therapeutics

(Get Free Report)

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.

Recommended Stories

Receive News & Ratings for Roquefort Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roquefort Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.